|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
NormOxys, Inc.' Novel Oxygen-Enhancing Drug Candidate, OXY111A, Recognized as One of Windhover Information Inc.'s Top 10 Cardiovascular/Metabolic Projects to Watch
11/3/2010 11:41:14 AM
WELLESLEY, Mass.--(BUSINESS WIRE)--NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body’s ability to deliver oxygen to diseased tissues and organs, today announced that OXY111A, its clinical stage candidate for the treatment of chronic heart failure and cancer, has been selected as one of Windover’s “Top 10 Cardiovascular/Metabolic Projects to Watch.” Along with inclusion in the “Top 10 to Watch” list, NormOxys is making a presentation today at Windhover’s Therapeutic Area Partnerships meeting, which is being held at the Westin Copley Place in Boston.
|
|
|
|
|
|
|
|
|
|
|